Bioxytran, INC 10-Q quarterly reports

Bioxytran Inc. reported a net loss of $2.07 million for Q1 2026, an increase from the prior year, while facing substantial doubt about its ability to continue as a going concern due to insufficient capital.

Bioxytran's Q3 2025 report reveals significant liquidity challenges and a going concern warning, despite increased R&D and recent capital raise efforts.

Bioxytran, a clinical-stage pharmaceutical company, reported a significant accumulated deficit and negative working capital, raising substantial doubt about its ability to continue operations without immediate capital infusion.

Bioxytran, Inc. reports a widened net loss for the first quarter of 2025 as it continues to focus on research and development of its pharmaceutical products.

Bioxytran reports ongoing losses and raises concerns about its ability to continue as a going concern, despite advancements in its drug development pipeline and a recent subsidiary acquisition.

Bioxytran, a clinical-stage pharmaceutical company, announced its Q2 2024 results, highlighting ongoing efforts to secure funding for continued drug development and regulatory approvals.

Bioxytran, Inc. files an amendment to its Q1 2024 quarterly report to correct a date error in the subsequent events disclosure related to common stock issuances.

Bioxytran, Inc. announces its financial results for the quarter ended March 31, 2024, highlighting ongoing efforts to develop therapeutic molecules and address financial challenges.